Corrections & Clarifications

2011

In Brief: Delayed-Release Risedronate (Atelvia)
The Medical Letter • Volume 53, March 21, 2011
Correction: The In-Brief article on delayed-release risedronate in issue 1360 included a statement that alendronate is currently the only bisphosphonate available generically. That would have been accurate if we had added "that is FDA-approved for treatment of osteoporosis." Etidronate (Didronel, and others), which was the first bisphosphonate used to treat osteoporosis (Medical Letter 1990; 32:111) but was never approved for such use by the FDA, is also available generically. It is approved for treatment of Paget's disease and for prevention and treatment of heterotropic ossification following hip replacement and in spinal-cord injured patients.
View the updated online version of this article.

Intravenous Acetaminophen (Ofirmev)
The Medical Letter • Volume 53, April 4, 2011
Clarification: The cost of ketorolac listed in Table 1 on page 27 is for a single 30-mg prefilled syringe. A 30-mg vial costs about $1.63 according to AWP listings in Red Book 2010.
View the updated online version of this article.

A New Testosterone Gel (Fortesta) for Hypogonadism
The Medical Letter • Volume 53, April 18, 2011
Correction: In Table 1, the price of a 5-mL (200 mg/mL) vial of testosterone enanthate should have been $79.30 for the generic and $91.30 for the brand (Delatestryl), not $15.86 for the generic and $18.26 for the brand.
View the updated online version of this article.

Dextromethorphan/Quinidine (Nuedexta) for Pseudobulbar Affect
The Medical Letter • Volume 53, June 13, 2011
Correction: In our June 13, 2011 article, we said that the FDA has approved Nuedexta for treatment of pseudobulbar affect in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). That is not quite correct. The package insert says that the drug is indicated for the treatment of pseudobulbar affect and then goes on to say, in the next two sentences, that studies to support the effectiveness of Nuedexta were performed in patients with underlying ALS or MS, and that the drug has not been shown to be safe or effective in other types of emotional lability. Also, the second sentence in the Drug Interactions paragraph should have said: "Other drugs that prolong the QT interval, inhibit CYP3A4, or are metabolized by CYP2D6 and prolong the QT interval, should be used with caution, if at all."
View the updated online version of this article.

Telaprevir (Incivek) and Boceprevir (Victrelis) for Chronic Hepatitis C
The Medical Letter • Volume 53, July 25, 2011
Correction: In the clinical studies section for telaprevir, "among patients who had a previous relapse" was added to the REALIZE trial sentence.
View the updated online version of this article.

Vemurafenib (Zelboraf) for Metastatic Melanoma
The Medical Letter • Volume 53, October 3, 2011
Correction: In the Dosage and Cost section on page 78, the minimum dose of vemurafenib was changed from 420 mg twice daily to 480 mg twice daily.
View the updated online version of this article.

A Fixed-Dose Combination of Ibuprofen and Famotidine (Duexis)
The Medical Letter • Volume 53, October 31, 2011
Correction:: In the clinical studies section, the overall incidence of endoscopic gastroduodenal ulcers should have been 11% with Duexis and 21.9% with ibuprofen alone and, in low dose aspirin users, 12.8% with Duexis and 32.8% with ibuprofen alone.
View the updated online version of this article.

Who Should Take Vitamin Supplements?
The Medical Letter • Volume 53, December 12/26, 2011
Revision: The first paragraph on vitamin E has been revised.
View the updated online version of this article.

2010

Ustekinumab (Stelara) for Psoriasis
The Medical Letter • Volume 52, January 25, 2010
Addendum: Footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.
View the updated online version of this article.

Ferumoxytol (Feraheme) – A New Parenteral Iron Formulation
The Medical Letter • Volume 52, March 22, 2010
Correction: The last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1 gram of sodium ferric gluconate (Ferrlecit) as about $600.
View the updated online version of this article.

Safety of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (COPD)
The Medical Letter • Volume 52, May 31, 2010
Correction: The last sentence in the Efficacy paragraph should say, "…budesonide/formoterol…" (not budesonide/salmeterol).
View the updated online version of this article.

A Sumatriptan Needle-Free Injection for Migraine
The Medical Letter • Volume 52, June 28, 2010
Correction: In Table 2, the injection volumes of Imitrex and Sumaval are listed as 5 mL. They should be 0.5 mL.
View the updated online version of this article.

Pitavastatin (Livalo) - The Seventh Statin
The Medical Letter • Volume 52, July 26, 2010
Correction: In the table, the usual decrease in LDL-cholesterol with pitavastatin has been changed to 35-40% (2 mg) and 40-45% (4 mg). Also, in the Dosage and Administration paragraph, the GFR has been changed to 30-<60 ml/min/1.73 m².
View the updated online version of this article.

Drugs for Parasitic Infections
Handbook (2nd Edition) • July 2010
Correction: In the table titled, "Manufacturers of Drugs Used to Treat Parasitic Infections", the first footnote on page 81 should say, " …(see footnote 3 on page 4)."

Drugs for Sexually Transmitted Infection
Treatment Guidelines • Volume 8, July 2010
Correction:The last two sentences in the Epididymitis section have been reworded.
View the updated online version of this article.

Mometasone/Formoterol (Dulera) for Asthma
The Medical Letter • Volume 52, October 18, 2010
Correction: In the Clinical Studies section, the second clinical trial compared the 2 different strengths of the combinations with mometasone alone, 400 mcg twice daily, and not with placebo.
View the updated online version of this article.

2009

Vancomycin Dosing and Monitoring
The Medical Letter • Volume 51, April 6, 2009
Correction: Dosing paragraph: The next to last sentence should be "...organism is =2 mg/L, the new...." (not >2 mg/L).
View the updated online version of this article.

Milnacipran (Savella) for Fibromyalgia
The Medical Letter • Volume 51, June 15, 2009
Correction: In the 2nd sentence, "similar to gabapentin" was added. It now reads, “...a gamma-aminobutyric acid (GABA) analog similar to gabapentin...”
View the updated online version of this article.

In Brief: Biennial IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis
The Medical Letter • Volume 51, June 29, 2009
Correction: The first word of the title was changed from Biannual to Biennial.
View the updated online version of this article.

Antimicrobial Prophylaxis for Surgery
Treatment Guidelines • Volume 7, June 2009
Addendum: Table 1: Footnote 14 was added to the Gastrointestinal/Colorectal section and a second sentence was added to footnote 5.
View the updated online version of this article.

Golimumab (Simponi) for Inflammatory Arthritis
The Medical Letter • Volume 51, July 13, 2009
Correction: In the first sentence "humanized" was changed to "human" to describe golimumab. In Table 1, the source for certolizumab (Cimzia) was changed to "humanized" and the price should have been $1,341.68 (not $3,136.40).
View the updated online version of this article.

Benzyl Alcohol Lotion for Head Lice
The Medical Letter • Volume 51, July 27, 2009
Correction: In Table 1, the price for lindane 1% shampoo should have been $136.86 (not $3.00).
View the updated online version of this article.

When a Statin Fails
The Medical Letter • Volume 51, July 27, 2009
Correction: The first paragraph should have included the words "for patients at high risk" after 100 mg/dL (2.6 mmol/L)
View the updated online version of this article.

Tapentadol (Nucynta) - A New Analgesic
The Medical Letter • Volume 51, August 10, 2009
Correction: In the pharmacokinetics table, the half-life for tapentadol was changed from "24" to "4".
View the updated online version of this article.

Colchicine and Other Drugs for Gout
The Medical Letter • Volume 51, November 30, 2009
Correction: In the Uricosuric agents paragraph, the last two words in the last sentence ("and theophylline.") were deleted.
View the updated online version of this article.

Advice for Travelers
Treatment Guidelines • Volume 7, November 2009
Correction: In the oral rehydration salts paragraph, the first sentence has been changed from "...can help maintain electrolyte balance..." to "can prevent and treat dehydration..."
View the updated online version of this article.

2008

Veregen: A Botanical for Treatment of Genital Warts
The Medical Letter • Volume 50, February 25, 2008
Correction: Theophylline was deleted from the pharmacology section on page 15; it is not among the components that make up 2.5% of the drug weight. Table 1: 2.3% discontinuation rate due to adverse effects for Veregen (not 5%)
View the updated online version of this article.

Diet, Drugs and Surgery for Weight Loss
Treatment Guidelines • Volume 6, April 2008
Correction: In the Adjustable Gastric Banding section on page 37, the first sentence has been changed from "Use of a laparoscopically adjustable gastric band placed around..." to "Use of an adjustable gastric band placed laparoscopically around..." In the second sentence, the words through a subcutaneous reservoir have been added.
View the updated online version of this article.

Natalizumab (Tysabri) for Crohn’s Disease
The Medical Letter • Volume 50, May 5, 2008
Correction: The May 5, 2008 article on the approval of natalizumab (Tysabri) for treatment of Crohn's disease in the "Adverse Effects" section on page 35 included the statement: "… postmarketing hepatotoxicity, sometimes fatal or requiring liver transplantation, has occurred." Actually, no fatal hepatotoxicity or liver transplantation has been reported to date. The FDA warning about post-marketing hepatotoxicity with Tysabri that was the basis for our statement said: "The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is recognized as an important predictor of severe liver injury that may lead to [emphasis added] death or the need for a liver transplant in some patients." Also, in the last sentence of the Conclusion, we should have said: "Because of the risk of serious hepatic toxicity and the rare but even more serious risk of developing progressive multifocal leukoencephalopathy, it should be used only in patients who have not responded to other drugs, including a TNF inhibitor." The italicized words should be substituted for "it is FDA-approved for use."
View the updated online version of this article.

Pharmacogenetic-Based Dosing of Warfarin
The Medical Letter • Volume 50, May 19, 2008
Addendum - Warfarin-Acetaminophen Interaction: A reader expressed disappointment that our recent listing of “Some Warfarin Drug Interactions” did not include acetaminophen. Perhaps it should have. Acetaminophen can increase the anticoagulant effect of warfarin, particularly with continued use, but it does so inconsistently. The mechanism of this interaction has not been established, but may be related to an acetaminophen metabolite inhibiting vitamin K-epoxide reductase, the target for warfarin’s anticoagulant effect.
View the updated online version of this article.

In Brief: Measles Outbreak
The Medical Letter • Volume 50, June 2, 2008
Illinois has been added to the first sentence. It is among the states where measles was reported.
View the updated online version of this article.

The EarCheck Middle Ear Monitor
The Medical Letter • Volume 50, July 14, 2008
Correction: The article in the July 14th issue contained an error in the last sentence of the last paragraph beginning on page 55. The instrument’s reading is determined not by the degree of protrusion of the tympanic membrane, but rather by its mobility.
View the updated online version of this article.

Drugs for Tobaco Dependence
Treatment Guidelines • Volume 6, September 2008
Table 1: Some footnotes were renumbered.
View the updated online version of this article.

Bendamustine (Treanda) for CLL and NHL
The Medical Letter • Volume 50, November 17, 2008
Correction: In the Clinical Studies section, the complete response rate with chlorambucil for CLL was 2% (not 24%).
View the updated online version of this article.

CT Colonography
The Medical Letter • Volume 50, December 1, 2008
Correction: In table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively. In the conclusion, "noninvasive" should be "less invasive."
View the updated online version of this article.

Drugs for Asthma
Treatment Guidelines • Volume 6, December 2008
Correction: In the table on page 86, the last sentence of footnote 7 was incomplete. It now correctly reads: "Zileuton is taken within 1 hour after morning and evening meals."
View the updated online version of this article.